Geneos Wealth Management’s Cardlytics CDLX Stock Holding History

Geneos Wealth Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2	Closed	-$3K	–	2884
2021 Q1	$3K	Buy	+2	New	+$2.64K	﹤0.01%	2781

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return

Geneos Wealth Management's CDLX Position: Q2 2021 in Review

Geneos Wealth Management sold out of Cardlytics (CDLX) in Q2 2021, closing a stake of 2 shares — an estimated $3K sold.

Geneos Wealth Management first reported a position in CDLX in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 189 funds tracked by Wall St. Rank hold CDLX as of Q2 2021.

Geneos Wealth Management reported no remaining Cardlytics position as of Q2 2021 after selling out during the quarter.
Geneos Wealth Management sold 2 Cardlytics shares in Q2 2021, an estimated $3K.
Geneos Wealth Management first reported a position in Cardlytics in Q1 2021 and held it in 1 quarter.
Geneos Wealth Management's Cardlytics position peaked at $3K in Q1 2021.
189 funds tracked by Wall St. Rank held Cardlytics as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.